Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing

Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer, as well as genomic alterations identified an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Sadakatsu, Elkin, Sheryl K., Tomson, Brett N., Carter, Jennifer L., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343723/
https://www.ncbi.nlm.nih.gov/pubmed/30339521
http://dx.doi.org/10.1080/15384047.2018.1523849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343723/
https://www.ncbi.nlm.nih.gov/pubmed/30339521
http://dx.doi.org/10.1080/15384047.2018.1523849

Ejemplares similares